Cargando…

Simple method for predicting muscle volume loss using geriatric nutritional risk index in hepatocellular carcinoma patients

Detalles Bibliográficos
Autores principales:	Hiraoka, Atsushi, Ohama, Hideko, Tada, Fujimasa, Fukunishi, Yoshiko, Yanagihara, Emi, Kato, Kanako, Kato, Masaya, Saneto, Hironobu, Izumoto, Hirofumi, Ueki, Hidetaro, Yoshino, Takeaki, Kitahata, Shogo, Kawamura, Tomoe, Kuroda, Taira, Suga, Yoshifumi, Miyata, Hideki, Hirooka, Masashi, Abe, Masanori, Matsuura, Bunzo, Ninomiya, Tomoyuki, Hiasa, Yoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401522/ https://www.ncbi.nlm.nih.gov/pubmed/37203385 http://dx.doi.org/10.1002/jcsm.13268

Ejemplares similares

Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment
por: Ohama, Hideko, et al.
Publicado: (2022)

Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria
por: Ohama, Hideko, et al.
Publicado: (2023)

Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma
por: Ohama, Hideko, et al.
Publicado: (2022)

Easy surveillance of muscle volume decline in chronic liver disease patients using finger‐circle (yubi‐wakka) test
por: Hiraoka, Atsushi, et al.
Publicado: (2019)

Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Factors Related to Sleeping Disorder Due to Pruritus in Patients with Chronic Liver Disease
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era
por: Nakamura, Yoshiko, et al.
Publicado: (2023)

SARC‐F combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

B cell activating factor in obesity is regulated by oxidative stress in adipocytes
por: Tada, Fujimasa, et al.
Publicado: (2013)

Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation
por: Hiraoka, Atsushi, et al.
Publicado: (2015)

Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality
por: Hiraoka, Atsushi, et al.
Publicado: (2023)

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease
por: Miyake, Teruki, et al.
Publicado: (2018)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Depletion of B cell-activating factor attenuates hepatic fat accumulation in a murine model of nonalcoholic fatty liver disease
por: Nakamura, Yoshiko, et al.
Publicado: (2019)

Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis
por: Yasuoka, Hidetaka, et al.
Publicado: (2020)

Association between Administration of Antithrombotics and Intraperitoneal Hemorrhage in Patients Undergoing Percutaneous Interventions for Liver Diseases
por: Asai, Akira, et al.
Publicado: (2021)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
por: Tada, Toshifumi, et al.
Publicado: (2022)

AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy
por: Watanabe, Takao, et al.
Publicado: (2021)

Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
por: Watanabe, Takao, et al.
Publicado: (2023)

Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
por: TADA, FUJIMASA, et al.
Publicado: (2012)

Effects of Motilin Receptor Agonists and Ghrelin in Human motilin receptor Transgenic Mice
por: Kawamura, Tomoe, et al.
Publicado: (2019)

Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis
por: Kitahata, Shogo, et al.
Publicado: (2021)

Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats
por: Fukunishi, Shinya, et al.
Publicado: (2014)

Role of B Cell-Activating Factor in Fibrosis Progression in a Murine Model of Non-Alcoholic Steatohepatitis
por: Kanemitsu-Okada, Kozue, et al.
Publicado: (2023)

Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Tanaka, Kazunari, et al.
Publicado: (2023)

Treatment on the Spleen Prevents the Progression of Secondary Sarcopenia in Patients With Liver Cirrhosis
por: Hirooka, Masashi, et al.
Publicado: (2020)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2021)

Protein Kinase R Modulates c-Fos and c-Jun Signaling to Promote Proliferation of Hepatocellular Carcinoma with Hepatitis C Virus Infection
por: Watanabe, Takao, et al.
Publicado: (2013)

Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan
por: Tada, Toshifumi, et al.
Publicado: (2017)

Relationship between body composition and the histology of non‐alcoholic fatty liver disease: a cross‐sectional study
por: Miyake, Teruki, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease is a risk factor for glucose intolerance onset in men regardless of alanine aminotransferase status
por: Miyake, Teruki, et al.
Publicado: (2021)

Plasma Fatty Acid Composition Is Associated with Histological Findings of Nonalcoholic Steatohepatitis
por: Miyake, Teruki, et al.
Publicado: (2022)

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice
por: Sujishi, Tetsuya, et al.
Publicado: (2015)

Efficacy and safety of laparoscopic hepatectomy for hepatocellular carcinoma comorbid with cirrhosis
por: Inoue, Yoshihiro, et al.
Publicado: (2020)

Hepatectomy and liver regeneration in the results of treatment of colorectal liver metastasis
por: Inoue, Yoshihiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nf64lt96i470s6o4rekjgga0q5